Table 4.

Clinicopathologic features of iAMP21 positive adolescent B-ALL without ETV6-RUNX1 fusion

Cases	Age(Yr)/Gender	WBC Count (109/L)	Additional Abnormalities	RUNX1 Copies/Cell	Outcome	References
1	15/M	3.1	−8,der(16)t(1;16),−21	5–6	CRb1 × 9 months	Johnson, 2015 [11]
2	17/M	2.4	Normal Karyotype	>5	Relapsed 58 months after diagnosis following SCT, CR2 × 3 y	Johnson, 2015 [11]
3	20/M	2.2	−13,−14,+21	6–7	CR1 × 30 months	Johnson, 2015 [11]
4	19/M	5.3	del(7)(q11.2)	5–9	CR alive for 2 years	Knez, 2015 [15]
5	13/M	3.7	None	5–10	Unknown	Knez, 2015 [15]
6	15/M	2.1	None	4–8	Relapsed after 7 years of CR	Knez, 2015 [15]
7	13/F	3.0	+X	>5	CR and alive for 3 years	Knez, 2015 [15]
8	15/M	15.8	del(7)(q31)	8	Relapse 2.5 y from diagnosis, CR2 at last chemo block	Haltrich, 2013 [12]
9	14/M	2.2	None	5–10	CR 29 months	Reichard, 2011 [8]
10	15/M	2.0	Not Done	6–8	CR 51 months	Reichard, 2011 [8]
11	13/F	2.8	None	5–10	CR 18 months	Soulier, 2003 [16]
12	17/M	1.0	add(1)(q25)	8	CR 19 months	Soulier, 2003 [16]
13	19/F	10.1	del(7)(p14p21)	6–8	CR 21 months	Soulier, 2003 [16]
14	14/M	2.2	inv(7)(p?15q?21)	5–7	CR 23 months	Soulier, 2003 [16]
15	13/F	3.8	del(7)(q22q35),del(11)(p12)	5	CR 61 months	Soulier, 2003 [16]
16	15/F	9.9	None	4	CR 86 months	Soulier, 2003 [16]
17	15/M	4.3	-Y	4–5	CR 32 months	Soulier, 2003 [16]
18	15/F	NAa	add(1)(p?),del(6)(q25)	>4	CR 13 months	Soulier, 2003 [16]
19	13/M	7.6	i(9)(q10),−16	4	CR 18 months	Soulier, 2003 [16]
20	13/F	6.6	add(4)(q31),del(7)(q3?2)	5	CR 10 months	Soulier, 2003 [16]
21	14/M	14.5	Normal Karyotype	6–15	CR 48 months	Soulier, 2003 [16]
22	15/F	NA	Normal Karyotype	15–20	Relapsed	Soulier, 2003 [16]

^a NA not available

^b CR complete remission